CLGN
Income statement / Annual
Last year (2024), CollPlant Biotechnologies Ltd.'s total revenue was $515.00 K,
a decrease of 95.30% from the previous year.
In 2024, CollPlant Biotechnologies Ltd.'s net income was -$16.61 M.
See CollPlant Biotechnologies Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$515.00 K |
$10.96 M |
$299.00 K |
$15.64 M |
$6.14 M |
$2.32 M |
$4.79 M |
$479.92 K |
$75.91 K |
$0.00 |
| Cost of Revenue |
$2.66 M
|
$3.09 M
|
$1.48 M
|
$2.01 M
|
$3.46 M
|
$2.27 M
|
$1.90 M
|
$306.09 K
|
$225.07 K
|
$202.82 K
|
| Gross Profit |
-$2.15 M
|
$7.87 M
|
-$1.18 M
|
$13.64 M
|
$2.68 M
|
$52.00 K
|
$3.11 M
|
$157.63 K
|
-$149.01 K
|
-$202.82 K
|
| Gross Profit Ratio |
-4.17
|
0.72
|
-3.94
|
0.87
|
0.44
|
0.02
|
0.65
|
0.33
|
-1.96
|
0
|
| Research and Development Expenses |
$10.52 M
|
$10.48 M
|
$10.26 M
|
$7.63 M
|
$3.66 M
|
$4.41 M
|
$5.16 M
|
$4.05 M
|
$4.36 M
|
$3.04 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.62 M
|
$3.29 M
|
$2.38 M
|
$2.86 M
|
$1.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.59 M
|
$4.89 M
|
$5.67 M
|
$5.94 M
|
$4.62 M
|
$3.62 M
|
$3.70 M
|
$2.30 M
|
$2.87 M
|
$1.78 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33.00 K
|
$21.51 K
|
$13.52 K
|
$9.88 K
|
$6.40 K
|
| Operating Expenses |
$15.10 M
|
$15.38 M
|
$15.92 M
|
$13.57 M
|
$8.28 M
|
$7.71 M
|
$7.68 M
|
$6.72 M
|
$10.26 M
|
$7.49 M
|
| Cost And Expenses |
$17.77 M
|
$18.47 M
|
$17.40 M
|
$15.58 M
|
$11.74 M
|
$9.95 M
|
$8.85 M
|
$6.45 M
|
$7.24 M
|
$4.82 M
|
| Interest Income |
$738.00 K
|
$788.00 K
|
$321.00 K
|
$219.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$17.00 K
|
$10.00 K
|
$34.00 K
|
$37.00 K
|
$34.00 K
|
$73.00 K
|
$26.00 K
|
$105.64 K
|
$15.89 K
|
$0.00
|
| Depreciation & Amortization |
$1.04 M
|
$1.10 M
|
$1.08 M
|
$773.00 K
|
$660.00 K
|
$539.00 K
|
$342.00 K
|
$291.63 K
|
$225.07 K
|
$201.86 K
|
| EBITDA |
-$15.55 M |
-$5.91 M |
-$15.82 M |
$1.05 M |
-$5.08 M |
-$10.55 M |
-$5.88 M |
-$5.41 M |
-$7.03 M |
-$4.60 M |
| EBITDA Ratio |
-30.2
|
-0.54
|
-52.89
|
0.07
|
-0.83
|
-4.55
|
-1.23
|
-11.27
|
-92.54
|
0
|
| Operating Income Ratio |
-33.5
|
-0.69
|
-57.18
|
0
|
-0.91
|
-3.29
|
-0.85
|
-12.44
|
-94.33
|
0
|
| Total Other Income/Expenses Net |
$642.00 K
|
$493.00 K
|
$172.00 K
|
$172.00 K
|
-$175.00 K
|
-$3.53 M
|
-$2.00 M
|
-$94.00 K
|
-$101.99 K
|
$50.87 K
|
| Income Before Tax |
-$16.61 M
|
-$7.02 M
|
-$16.93 M
|
$237.00 K
|
-$5.77 M
|
-$11.16 M
|
-$3.69 M
|
-$6.01 M
|
-$7.25 M
|
-$4.78 M
|
| Income Before Tax Ratio |
-32.25
|
-0.64
|
-56.61
|
0.02
|
-0.94
|
-4.82
|
-0.77
|
-12.52
|
-95.52
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.96 M
|
$28.44 K
|
$0.00
|
$63.85 K
|
| Net Income |
-$16.61 M
|
-$7.02 M
|
-$16.93 M
|
$237.00 K
|
-$5.77 M
|
-$11.16 M
|
-$6.25 M
|
-$5.80 M
|
-$7.27 M
|
-$4.80 M
|
| Net Income Ratio |
-32.25
|
-0.64
|
-56.61
|
0.02
|
-0.94
|
-4.82
|
-1.31
|
-12.1
|
-95.72
|
0
|
| EPS |
-1.45 |
-0.62 |
-1.52 |
0.041 |
-0.84 |
-2.95 |
-1.43 |
-2.27 |
-3.6 |
-2.83 |
| EPS Diluted |
-1.45 |
-0.62 |
-1.52 |
0.0342 |
-0.84 |
-2.95 |
-1.43 |
-2.27 |
-3.6 |
-2.83 |
| Weighted Average Shares Out |
$11.45 M
|
$11.39 M
|
$11.03 M
|
$9.97 M
|
$6.89 M
|
$4.99 M
|
$4.38 M
|
$2.66 M
|
$2.01 M
|
$1.69 M
|
| Weighted Average Shares Out Diluted |
$11.45 M
|
$11.39 M
|
$11.03 M
|
$11.97 M
|
$6.89 M
|
$4.99 M
|
$4.38 M
|
$2.66 M
|
$2.01 M
|
$1.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
